Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Healthscope commences clinical validation study of Circadian’s Cancer Diagnostic (ASX:CIR)

Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) announced today that Healthscope Limited, its licensee and development partner for a novel diagnostic technology for “Cancers of Unknown...read more

Retirements from Circadian Board of Directors (ASX:CIR)

Circadian announces today that Dr Jonathan Skipper has provided notice that he will retire as a director of the board effective 24 November 2011 at the Annual General Meeting (AGM) and that Mr Carl...read more

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors (ASX:CIR)

Melbourne, Australia September 30, 2011 – Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted ...read more

VGX-100 identified as potential new therapy for Dry Eye Disease (ASX:CIR)

Melbourne, Australia September 13, 2011– Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) announced today the publication of data in the scientific journal Archives of Ophthalmology sho...read more

Circadian makes key appointment in clinical trials management (ASX:CIR)

Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) is pleased to announce that it has appointed Dr Ian Leitch to the newly created position of Director – Clinical Research effective from 1...read more

VEGF-C and VEGF-D identified as biomarkers for Avastin resistance in colorectal cancer patients (ASX:CIR)

- Data presented at American Society for Clinical Oncology (“ASCO”) Annual meeting in Chicago - Data obtained from 42 patients treated with chemotherapy (5-flourouracil and irinotecan...read more

Van Leeuwenhoeck Research (ASX:CIR)

Initiating Coverage Report 3. Technology Circadian is developing a variety of drugs to block the interaction between VEGF Receptor-3 (VEGFR-3) and its ligands VEGF-C and VEGF-D. Drugs...read more

Investment summary: Dawn of VEGF-C therapy (ASX:CIR)

Circadian Technologies is now focused on developing VGX-100, a VEGF-C inhibitory monoclonal antibody. Trials will start in late 2011. If safety studies complete as expected, VGX-100 is scheduled to...read more

Circadian’s VGX-100 Inhibits Tumour Growth in Models of Lung, Ovarian and Prostate Cancer (ASX:CIR)

Circadian’s VGX-100 Inhibits Tumour Growth in Models of Lung, Ovarian and Prostate Cancer Data demonstrates efficacy of VGX-100 with other therapeutic agents in mouse models of lung, ova...read more

CIRCADIAN LAUNCHES FIRST DIAGNOSTIC FOR LAM LUNG DISEASE WITH U.S. PARTNER (ASX:CIR)

- Circadian and Cincinnati Children’s Hospital Medical Center (“Cincinnati Children’s”) commences offering of first blood test diagnostic for LAM – a serious lung dise...read more

Viewing: 46 - 60 of 55 Previous | Next